Our VisionTo be the preferred partner for the world’s leading specialty pharmaceutical and generic companies.

Our misionOperating a State-Of-The-Art US FDA, EU GMP compliant finished formulations facility bolstered by a team of the best scientists, engineers, and professionals in India.

Our Values

collaboration

Collaboration

science-decisions

Innovation &
science-based
decisions

Accountability

Accountability

agility-sustainability

Agility
Sustainability

Key Timeline

Innoxel is an emerging Contract Development and Manufacturing Organization (CDMO)

Innoxel Lifesciences, headquartered in Vadodara, India, specializes in the aseptic and terminal sterilized production of injectable vials, pre-filled syringes, and oral liquids. As a comprehensive pharmaceutical company, we possess Research & Formulation Development and manufacturing capabilities, particularly in patented drug-delivery formulations within specialized therapies like oncology and critical care. Our primary focus is on regulated markets such as the USA, to enhance India's expanding global market footprint by ensuring unmatched quality standards.

Established in 2020, Innoxel Lifesciences stands out as a unique greenfield site. We have meticulously planned, constructed, and are currently operational, ensuring adherence to EU GMP, UK MHRA, and US FDA standards. The initial batch of ANDA filings with the US FDA via Innoxel is scheduled for Q1 2024, setting the stage for a potential US FDA inspection in early 2025.

Innovate. Collaborate. Elevate.
Start Your Journey with Innoxel!

cdmo-banner